NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Multimodal Imaging of MS Reveals the Smoldering Inflammation

Active Not RecruitingN/A

Sponsor: Turku University Hospital

Conditions: Multiple Sclerosis

Countries: Finland

To evaluate active MS plaque evolution with conventional MRI, QSM-post processing, TSPO-PET imaging and P2X7-PET imaging.

Eligibility overview

Sex: ALL

Age: 18 Years to 70 Years

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria

Active MS-patients:

* Informed consent form
* At least one 0,5 cm diameter active gadolinium enhancing lesion detected lately
* Diagnosed MS-disease according to McDonald criteria

SPMS patients

* Informed consent form
* Diagnosed MS-disease according to McDonald criteria
* SPMS disease

Healthy controls:

* Informed consent form
* healthy
* age and sex matched with MS-patients in RRMS and SPMS groups

Exclusion Criteria

MS-patients:

* Patients suffering from another brain disease or other autoimmune disease in addition to multiple sclerosis
* Steroid treatment 4 weeks prior to the scan
* Significant pathology in the MRI scan other than MS-related lesions
* Patients suffering from claustrophobia or panic disorder, or patients who have exhibited hypersensitivity of PET markers (practical obstacle to the scan)
* Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study
* Age over 70

Healthy controls:

* autoimmune disease, CNS disease or other serious disease
* Steroid treatment 4 weeks prior to the scan or other regular medication
* persons suffering from claustrophobia or panic disorder, or persons who have exhibited hypersensitivity of PET markers (practical obstacle to the scan)
* Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study
* Age over 70

Locations (1)

Turku, Southwest Finland, Finland